NASDAQ:PRQR ProQR Therapeutics (PRQR) Stock Forecast, Price & News $1.44 +0.19 (+15.20%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$1.18▼$1.5850-Day Range$1.25▼$1.6352-Week Range$0.79▼$3.85Volume1.25 million shsAverage Volume636,273 shsMarket Capitalization$116.38 millionP/E RatioN/ADividend YieldN/APrice Target$3.88 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media ProQR Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside169.7% Upside$3.88 Price TargetShort InterestHealthy1.81% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.92Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.28) to ($0.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.78 out of 5 starsMedical Sector797th out of 967 stocksPharmaceutical Preparations Industry362nd out of 434 stocks 3.4 Analyst's Opinion Consensus RatingProQR Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.88, ProQR Therapeutics has a forecasted upside of 169.7% from its current price of $1.44.Amount of Analyst CoverageProQR Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.81% of the float of ProQR Therapeutics has been sold short.Short Interest Ratio / Days to CoverProQR Therapeutics has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in ProQR Therapeutics has recently decreased by 3.55%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldProQR Therapeutics does not currently pay a dividend.Dividend GrowthProQR Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRQR. Previous Next 2.7 News and Social Media Coverage News SentimentProQR Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ProQR Therapeutics this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProQR Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.40% of the stock of ProQR Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 26.15% of the stock of ProQR Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ProQR Therapeutics are expected to decrease in the coming year, from ($0.28) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProQR Therapeutics is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProQR Therapeutics is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProQR Therapeutics has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ProQR Therapeutics (NASDAQ:PRQR) StockProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions, as well as other targets in its discovery pipeline. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.Read More PRQR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRQR Stock News HeadlinesOctober 3, 2023 | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) vs. Enveric Biosciences (NASDAQ:ENVB) Financial ContrastSeptember 28, 2023 | finance.yahoo.comProQR Announces Participation in the Chardan 7th Annual Genetic Medicines ConferenceOctober 4, 2023 | Stansberry Research (Ad)Is NVIDIA Leading a "Magnificent Seven Bubble"?The world’s massive tech leaders may be in a bubble, led by NVIDIA’s enormous rise this year. What happens next could affect all stocks. September 27, 2023 | finance.yahoo.comProQR Therapeutics Provides Update on Ophthalmic AssetsSeptember 7, 2023 | finance.yahoo.comProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment ConferenceAugust 8, 2023 | finance.yahoo.comProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are retail investors with 50% stake, while 31% is held by institutionsAugust 4, 2023 | msn.comChardan Capital Reiterates ProQR Therapeutics N.V (PRQR) Neutral RecommendationAugust 4, 2023 | markets.businessinsider.com4 Analysts Have This to Say About ProQR TherapeuticsOctober 4, 2023 | Stansberry Research (Ad)Is NVIDIA Leading a "Magnificent Seven Bubble"?The world’s massive tech leaders may be in a bubble, led by NVIDIA’s enormous rise this year. What happens next could affect all stocks. August 3, 2023 | uk.finance.yahoo.comProQR Announces Second Quarter 2023 Operating and Financial ResultsAugust 2, 2023 | technews.tmcnet.comProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic AssetsAugust 1, 2023 | finance.yahoo.comProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic AssetsJuly 18, 2023 | finance.yahoo.comPRQR Oct 2023 7.500 callJune 28, 2023 | stocknews.com2 Biotech Stocks to Buy, 1 to Sell NowJune 28, 2023 | finance.yahoo.comProQR Therapeutics' (NASDAQ:PRQR) investors will be pleased with their impressive 109% return over the last yearMay 23, 2023 | markets.businessinsider.comChardan Capital Remains a Hold on ProQR (PRQR)May 18, 2023 | finance.yahoo.comProQR Therapeutics N.V. (NASDAQ:PRQR) Could Be Less Than A Year Away From ProfitabilityMay 17, 2023 | msn.comHC Wainwright & Co. Reiterates ProQR Therapeutics N.V (PRQR) Buy RecommendationMay 17, 2023 | msn.comJMP Securities Reiterates ProQR Therapeutics N.V (PRQR) Market Outperform RecommendationMay 17, 2023 | msn.comAnalyst Ratings for ProQR TherapeuticsMay 17, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for ProQR (PRQR)May 16, 2023 | msn.comRecap: ProQR Therapeutics Q1 EarningsMay 16, 2023 | finance.yahoo.comProQR Announces First Quarter 2023 Operating and Financial ResultsMay 9, 2023 | finance.yahoo.comProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023April 20, 2023 | finance.yahoo.comProQR Announces Upcoming Investor Conferences in April and MayApril 18, 2023 | finance.yahoo.comProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023March 31, 2023 | benzinga.comProQR Therapeutics Stock (NASDAQ:PRQR), Earnings Estimates, EPS, and RevenueSee More Headlines Receive PRQR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PRQR Company Calendar Last Earnings8/03/2023Today10/04/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRQR CUSIPN/A CIK1612940 Webwww.proqr.com Phone(188) 166-7000FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.88 High Stock Price Forecast$5.00 Low Stock Price Forecast$1.80 Forecasted Upside/Downside+169.7%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,600,000.00 Net Margins-1,427.27% Pretax Margin-1,433.16% Return on Equity-86.23% Return on Assets-34.38% Debt Debt-to-Equity Ratio0.07 Current Ratio5.71 Quick Ratio5.71 Sales & Book Value Annual Sales$4.25 million Price / Sales27.38 Cash FlowN/A Price / Cash FlowN/A Book Value$0.85 per share Price / Book1.69Miscellaneous Outstanding Shares80,820,000Free Float74,028,000Market Cap$116.38 million OptionableOptionable Beta0.09 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Domenico Valerio Ph.D. (Age 67)Founder & Independent Chairman of Supervisory Board Comp: $78.97kMr. Daniel Anton de Boer (Age 40)Founder, CEO & Member of Management Board Comp: $1.41MMr. Rene K. Beukema (Age 59)Chief Corp. Devel. Officer, Gen. Counsel & Member of Management Board Comp: $313.76kDr. Gerard Platenburg (Age 59)Co-Founder & Chief Scientific Officer Mr. Jurriaan Dekkers (Age 47)Chief Financial Officer Ms. Sheila Sponselee (Age 39)VP & Head of People and Operations Ms. Sarah Cue KielyVP of Investor Relations & Corp. CommunicationsMs. Sandra van der KolkJr. Financial ControllerMore ExecutivesKey CompetitorsInflaRxNASDAQ:IFRXXBiotechNASDAQ:XBITGalectin TherapeuticsNASDAQ:GALTPuma BiotechnologyNASDAQ:PBYIReviva PharmaceuticalsNASDAQ:RVPHView All CompetitorsInstitutional OwnershipCitadel Advisors LLCSold 48,800 shares on 8/15/2023Ownership: 0.000%Marshall Wace LLPSold 317,467 shares on 8/14/2023Ownership: 0.383%Renaissance Technologies LLCBought 200,499 shares on 8/11/2023Ownership: 0.248%JPMorgan Chase & Co.Sold 42,179 shares on 8/11/2023Ownership: 0.223%Monaco Asset Management SAMBought 58,183 shares on 8/8/2023Ownership: 0.294%View All Institutional Transactions PRQR Stock - Frequently Asked Questions Should I buy or sell ProQR Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRQR shares. View PRQR analyst ratings or view top-rated stocks. What is ProQR Therapeutics' stock price forecast for 2023? 6 brokerages have issued 12 month price objectives for ProQR Therapeutics' stock. Their PRQR share price forecasts range from $1.80 to $5.00. On average, they predict the company's share price to reach $3.88 in the next year. This suggests a possible upside of 169.7% from the stock's current price. View analysts price targets for PRQR or view top-rated stocks among Wall Street analysts. How have PRQR shares performed in 2023? ProQR Therapeutics' stock was trading at $3.70 at the beginning of the year. Since then, PRQR shares have decreased by 61.1% and is now trading at $1.44. View the best growth stocks for 2023 here. When is ProQR Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our PRQR earnings forecast. How were ProQR Therapeutics' earnings last quarter? ProQR Therapeutics (NASDAQ:PRQR) issued its quarterly earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. The biopharmaceutical company earned $1.31 million during the quarter, compared to analysts' expectations of $2.77 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 86.23% and a negative net margin of 1,427.27%. What ETF holds ProQR Therapeutics' stock ? Morningstar US Small Growth holds 21,680 shares of PRQR stock, representing 1.52% of its portfolio. What other stocks do shareholders of ProQR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX). What is ProQR Therapeutics' stock symbol? ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR." How do I buy shares of ProQR Therapeutics? Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ProQR Therapeutics' stock price today? One share of PRQR stock can currently be purchased for approximately $1.44. How much money does ProQR Therapeutics make? ProQR Therapeutics (NASDAQ:PRQR) has a market capitalization of $116.38 million and generates $4.25 million in revenue each year. The biopharmaceutical company earns $-68,600,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. How many employees does ProQR Therapeutics have? The company employs 130 workers across the globe. How can I contact ProQR Therapeutics? ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The official website for the company is www.proqr.com. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at ir@proqr.com. This page (NASDAQ:PRQR) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.